Amgen (AMGN): Reasons Neulasta May Not Be Approved - Jefferies
Tweet Send to a Friend
Jefferies analyst, Michael Yee, reiterated his Buy rating on shares of Amgen (NASDAQ: AMGN) noting that 2018-2020 consensus may be ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


